CSL Behring is committed to safety, quality, and the customers we serve CSL Behring is a world leader in specialty biopharmaceuticals and is committed to people around the world with rare and serious conditions, such as hereditary angioedema (HAE).

We're dedicated to making a difference in the HAE community through education, services, and other resources for patients and families affected by the condition.

CSL Behring has established the Berinert Expert Network (B.E.N.®), a resource designed to:

  • Assist you in starting Berinert therapy
  • Connect you to the HAE patient community
  • Help you work through insurance issues and questions
  • Give you an opportunity to share your experiences with your peers via the B.E.N. P.A.L.S. patient advocate program
  • Helping to reduce your out-of-pocket co-pay costs through the Co-Pay BENefit™ program
  • Provide peace of mind through CSL Behring's Assurance™ and Assistance programs

We sponsor AllAboutHAE.com, an online HAE resource with useful information, such as an interactive treatment journal.

We are a proud supporter of the US Hereditary Angioedema Association, a nonprofit patient advocacy organization dedicated to expediting US approval of safer and more effective HAE therapies. The organization provides a wide range of services that include clinical trial placement, physician referrals, education, and individualized patient case management.

CSL Behring is also committed to those who are uninsured or underinsured, as well as those who experience a gap in coverage. To learn more about our assistance programs, please visit the Resources and Support section.

*Peer supporters are not healthcare professionals or medical experts. For medical questions, patients should contact their physicians.

Talk with your doctor about starting with Berinert on-demand therapy, learn how to recognize signs and when to administer Berinert.

Home Choose On-Demand Treatment CSL Behring Commitment

Important Safety Information

BERINERT®, C1 Esterase Inhibitor (Human), is used in adults and children to treat swelling and/or painful attacks of hereditary angioedema (HAE) affecting the abdomen, face or throat. The safety and efficacy of BERINERT in preventing HAE attacks have not been established.

Do not use BERINERT if you have experienced life-threatening allergic reactions or severe hypersensitivity to the product. Inform your healthcare provider of all medications you are taking and of any medical conditions, especially any history of blood-clotting problems.

Blood clots have occurred in patients receiving BERINERT. Tell your healthcare provider if you have a history of heart or blood vessel disease, stroke, or blood clots, or if you have thick blood, an indwelling catheter/access device in a vein, or have been immobile for some time. Certain medications, such as birth control pills, may also increase your risk of clotting problems.

Report to your physician or an emergency room any signs and symptoms of a blood clot, including pain and/or swelling or discoloration of an arm or leg, with warmth over affected area; unexplained shortness of breath; chest pain or discomfort that worsens on deep breathing; rapid pulse; and numbness or weakness on one side of the body.

In addition, report immediately any signs or symptoms of allergic reactions to BERINERT, including hives, chest tightness, wheezing, difficulty breathing, turning blue, faintness, facial swelling and fast heartbeat.

If you have been trained to self-administer BERINERT, immediately prepare the prescribed dose at the first symptoms of an attack. Seek immediate medical attention and do not begin to self-administer if an HAE attack has progressed to a point where you will be unable to prepare or administer a dose of BERINERT.

If you self-administer to treat a laryngeal attack, immediately seek medical attention afterward. If you self-administer for an abdominal attack, inform your physician so that other possible causes can be ruled out.

Call your doctor right away if swelling is not controlled after use of BERINERT.

In clinical studies, the most serious adverse reaction reported in subjects who received BERINERT was an increased severity of the pain associated with HAE. In the placebo-controlled clinical trial, the most common adverse reaction reported more often among subjects who received BERINERT than those receiving placebo was dysgeusia (a bad taste in mouth). Tell your healthcare provider about any side effect that bothers you or does not go away.

Because BERINERT is made from human blood, the risk that it may transmit infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

Please see full prescribing information for BERINERT, including the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

CSL Behring
© 2018 CSL Behring. The product information presented on this site is intended for US residents only. BRN/03-13-0059(1)d